nach oben

Clinical Rheumatology

Erschienen in:

27.03.2023 | CASE BASED REVIEW

Bortezomib is efficacious in the treatment of severe childhood-onset neuropsychiatric systemic lupus erythematosus with psychosis: a case series and mini-review of B-cell immunomodulation in antibody-mediated diseases

verfasst von: Renee F. Modica, Akaluck Thatayatikom, Denise H. Bell-Brunson, Melissa E. Elder

Erschienen in: Clinical Rheumatology | Ausgabe 7/2023

Einloggen, um Zugang zu erhalten

Abstract

Childhood-onset neuropsychiatric systemic lupus erythematosus (cNPSLE) with psychosis is a challenging manifestation of SLE. Pathogenic long-lived plasma cells (LLPCs) are not specifically targeted by standard immunosuppression and their persistence contributes to chronic autoimmunity. Bortezomib is approved for the treatment of multiple myeloma and has shown benefits in a variety of other antibody-mediated diseases. Bortezomib may be efficacious for severe or treatment-refractory cNPSLE through eradication of LLPCs, decreasing autoantibody production. We describe the first pediatric case series of five patients with unrelenting cNPSLE with psychosis who were treated safely and effectively with bortezomib between 2011 and 2017. Most patients had persistent cNPSLE with psychosis despite aggressive immunosuppression with methylprednisolone, cyclophosphamide, rituximab, and usually plasmapheresis. All patients demonstrated rapid clinical improvement in their psychotic manifestations with the ability to quickly taper immunosuppression after the introduction of bortezomib. No patient had a recurrence of overt psychosis during a follow-up period of 1–10 years. Secondary hypogammaglobulinemia developed in all five patients and required immunoglobulin replacement. No other severe side effects or adverse events were observed. Bortezomib-mediated LLPC depletion is a promising therapy for severe recalcitrant cNPSLE with psychosis when used as adjunctive therapy to conventional immunosuppression, B-cell, and antibody-depleting therapies. After initiation of bortezomib, patients had rapid, demonstrable improvement in psychosis as well as reduction in glucocorticoids and antipsychotics. Further investigation is needed to determine the therapeutic role of bortezomib in severe cNPSLE and cSLE. We present a mini-review of the rationale for bortezomib use and novel B-cell immunomodulation in rheumatic disease.

Schwartz N, Stock AD, Putterman C (2019) Neuropsychiatric lupus: new mechanistic insights and future treatment directions. Nat Rev Rheumatol 15(3):137–152. https://doi.org/10.1038/s41584-018-0156-8CrossRefPubMedPubMedCentral

Pego-Reigosa JM, Isenberg DA (2008) Psychosis due to systemic lupus erythematosus: characteristics and long-term outcome of this rare manifestation of the disease. Rheumatology (Oxford, England) 47(10):1498–1502. https://doi.org/10.1093/rheumatology/ken260CrossRefPubMed

Zhu TY, Tam LS, Lee VW, Lee KK, Li EK (2009) The impact of flare on disease costs of patients with systemic lupus erythematosus. Arthritis Rheum 61(9):1159–1167. https://doi.org/10.1002/art.24725CrossRefPubMed

Giani T, Smith EM, Al-Abadi E, Armon K, Bailey K, Ciurtin C, Davidson J, Gardner-Medwin J, Haslam K, Hawley DP, Leahy A, Leone V, McErlane F, Mewar D, Modgil G, Moots R, Pilkington C, Pregnolato F, Ramanan AV, Rangaraj S, Riley P, Sridhar A, Wilkinson N, Cimaz R, Beresford MW, Hedrich CM (2021) Neuropsychiatric involvement in juvenile-onset systemic lupus erythematosus: data from the UK Juvenile-onset systemic lupus erythematosus cohort study. Lupus 30(12):1955–1965. https://doi.org/10.1177/09612033211045050CrossRefPubMedPubMedCentral

Bartolucci P, Bréchignac S, Cohen P, Le Guern V, Guillevin L (2007) Adjunctive plasma exchanges to treat neuropsychiatric lupus: a retrospective study on 10 patients. Lupus 16(10):817–822. https://doi.org/10.1177/0961203307081840CrossRefPubMed

Narváez J, Ríos-Rodriguez V, de la Fuente D, Estrada P, López-Vives L, Gómez-Vaquero C, Nolla JM (2011) Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum 41(3):364–372. https://doi.org/10.1016/j.semarthrit.2011.06.004CrossRefPubMed

Hoyer BF, Manz RA, Radbruch A, Hiepe F (2005) Long-lived plasma cells and their contribution to autoimmunity. Ann N Y Acad Sci 1050:124–133. https://doi.org/10.1196/annals.1313.014CrossRefPubMed

Streicher K, Morehouse CA, Groves CJ, Rajan B, Pilataxi F, Lehmann KP, Brohawn PZ, Higgs BW, McKeever K, Greenberg SA, Fiorentino D, Richman LK, Jallal B, Herbst R, Yao Y, Ranade K (2014) The plasma cell signature in autoimmune disease. Arthritis Rheumatol (Hoboken, NJ) 66(1):173–184. https://doi.org/10.1002/art.38194CrossRef

Hiepe F, Dörner T, Hauser AE, Hoyer BF, Mei H, Radbruch A (2011) Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 7(3):170–178. https://doi.org/10.1038/nrrheum.2011.1CrossRefPubMed

10.

Hiepe F, Radbruch A (2016) Plasma cells as an innovative target in autoimmune disease with renal manifestations. Nat Rev Nephrol 12(4):232–240. https://doi.org/10.1038/nrneph.2016.20CrossRefPubMed

11.

Khodadadi L, Cheng Q, Alexander T, Sercan-Alp O, Klotsche J, Radbruch A, Hiepe F, Hoyer BF, Taddeo A (2015) Bortezomib plus continuous B cell depletion results in sustained plasma cell depletion and amelioration of lupus nephritis in NZB/W F1 mice. PloS one 10(8):e0135081. https://doi.org/10.1371/journal.pone.0135081CrossRefPubMedPubMedCentral

12.

Morrow WR, Frazier EA, Mahle WT, Harville TO, Pye SE, Knecht KR, Howard EL, Smith RN, Saylors RL, Garcia X, Jaquiss RD, Woodle ES (2012) Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation 93(3):319–324. https://doi.org/10.1097/TP.0b013e31823f7eeaCrossRefPubMedPubMedCentral

13.

Zinn MD, L’Ecuyer TJ, Fagoaga OR, Aggarwal S (2014) Bortezomib use in a pediatric cardiac transplant center. Pediatr Transplant 18(5):469–476. https://doi.org/10.1111/petr.12300CrossRefPubMed

14.

Gomez AM, Willcox N, Vrolix K, Hummel J, Nogales-Gadea G, Saxena A, Duimel H, Verheyen F, Molenaar PC, Buurman WA, De Baets MH, Martinez-Martinez P, Losen M (2014) Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients. Journal of immunology (Baltimore, Md : 1950) 193(3):1055–1063. https://doi.org/10.4049/jimmunol.1301555CrossRefPubMed

15.

Wang Y, Zhou W, Zhang Z (2015) Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient. Rheumatology (Oxford, England) 54(1):194–195. https://doi.org/10.1093/rheumatology/keu393CrossRefPubMed

16.

Khandelwal P, Davies SM, Grimley MS, Jordan MB, Curtis BR, Jodele S, Marsh R, Filipovich AH (2014) Bortezomib for refractory autoimmunity in pediatrics. Biol Blood Marrow Transplant : J Am Soc Blood Marrow Transplant 20(10):1654–1659. https://doi.org/10.1016/j.bbmt.2014.06.032CrossRef

17.

Alexander T, Sarfert R, Klotsche J, Kuhl AA, Rubbert-Roth A, Lorenz HM, Rech J, Hoyer BF, Cheng Q, Waka A, Taddeo A, Wiesener M, Schett G, Burmester GR, Radbruch A, Hiepe F, Voll RE (2015) The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 74(7):1474–1478. https://doi.org/10.1136/annrheumdis-2014-206016CrossRefPubMed

18.

Ishii T, Tanaka Y, Kawakami A, Saito K, Ichinose K, Fujii H, Shirota Y, Shirai T, Fujita Y, Watanabe R, Chiu SW, Yamaguchi T, Harigae H (2018) Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus. Mod Rheumatol 28(6):986–992. https://doi.org/10.1080/14397595.2018.1432331CrossRefPubMed

19.

Segarra A, Arredondo KV, Jaramillo J, Jatem E, Salcedo MT, Agraz I, Ramos N, Carnicer C, Valtierra N, Ostos E (2020) Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience. Lupus 29(2):118–125. https://doi.org/10.1177/0961203319896018CrossRefPubMed

20.

Tkachenko O, Lapin S, Maslyansky A, Myachikova V, Mikhailova L, Gilburd B (2019) Relapsing Evans syndrome and systemic lupus erythematosus with antiphospholipid syndrome treated with Bortezomib in combination with plasma exchange. Clin Immunol 199:44–46. https://doi.org/10.1016/j.clim.2018.12.010CrossRefPubMed

21.

Scheibe F, Pruss H, Mengel AM, Kohler S, Numann A, Kohnlein M, Ruprecht K, Alexander T, Hiepe F, Meisel A (2017) Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis. Neurology 88(4):366–370. https://doi.org/10.1212/wnl.0000000000003536CrossRefPubMed

22.

Shin YW, Lee ST, Kim TJ, Jun JS, Chu K (2018) Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis. Ann Clin Transl Neurol 5(5):598–605. https://doi.org/10.1002/acn3.557CrossRefPubMedPubMedCentral

23.

Zhang C, Tian DC, Yang CS, Han B, Wang J, Yang L, Shi FD (2017) Safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder. JAMA Neurol 74(8):1010–1012. https://doi.org/10.1001/jamaneurol.2017.1336CrossRefPubMedPubMedCentral

24.

Kim SH (2018) Bortezomib for neuromyelitis optica spectrum disorder: a new therapeutic option for the more severe forms? JAMA Neurol 75(1):128–129. https://doi.org/10.1001/jamaneurol.2017.3447CrossRefPubMed

25.

Liang MH, Corzillius M, Bae SC, Lew RA, Fortin PR, Gordon C, Isenberg D, Alarcón GS, Straaton KV, Denburg J, Denburg S, Esdaile JM, Glanz BI, Karlson EW, Khoshbin S, Rogers MP, Schur PH, Hanly JG, Kozora E, West S, Lahita RG, Lockshin MD, McCune J, Moore PM, Petri M, Roberts WN, Sanchez-Guerrero J, Veilleux M, Brey R, Cornblath WD, Filley CM, Fisk JD, Harten P, Hay EM, Iverson G, Levine SR, Waterhouse E, Wallace DJ, Winer JB (1999) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 42(4)599–608. https://doi.org/10.1002/1529-0131(199904)42:4<599::Aid-anr2>3.0.Co;2-f

26.

Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 12(5):431–440. https://doi.org/10.1016/s1470-2045(11)70081-xCrossRefPubMed

27.

Bonilla-Abadía F, Coronel Restrepo N, Tobón GJ, Echeverri AF, Muñoz-Buitrón E, Castro AM, Bejarano MA, Cañas CA (2014) Rituximab for remission induction and maintenance in refractory systemic lupus erythematosus. Autoimmune Dis 2014:731806. https://doi.org/10.1155/2014/731806CrossRefPubMedPubMedCentral

28.

Fowler NH (2011) Role of maintenance rituximab (rituxan) therapy in the treatment of follicular lymphoma. P t 36(9):590–598PubMedPubMedCentral

29.

Brunner HI, Higgins GC, Klein-Gitelman MS, Lapidus SK, Olson JC, Onel K, Punaro M, Ying J, Giannini EH (2010) Minimal clinically important differences of disease activity indices in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 62(7):950–959. https://doi.org/10.1002/acr.20154CrossRefPubMed

30.

Mike EV, Makinde HM, Der E, Stock A, Gulinello M, Gadhvi GT, Winter DR, Cuda CM, Putterman C (2018) Neuropsychiatric systemic lupus erythematosus is dependent on sphingosine-1-phosphate signaling. Front Immunol 9:2189. https://doi.org/10.3389/fimmu.2018.02189CrossRefPubMedPubMedCentral

31.

Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T, Barnard J, Nevarez S, Goldman BI, Kirk CJ, Looney RJ, Anolik JH (2012) Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum 64(2):493–503. https://doi.org/10.1002/art.33333CrossRefPubMedPubMedCentral

32.

Griger Z, Toth BI, Barath S, Gyetvai A, Kovacs I, Tarr T, Biro T, Zeher M, Sipka S (2012) Different effects of bortezomib on the expressions of various protein kinase C isoenzymes in T cells of patients with systemic lupus erythematosus and in Jurkat cells. Scand J Immunol 75(2):243–248. https://doi.org/10.1111/j.1365-3083.2011.02647.xCrossRefPubMed

33.

Mohty M, Brissot E, Savani BN, Gaugler B (2013) Effects of bortezomib on the immune system: a focus on immune regulation. Biol Blood Marrow Transplant : J Am Soc Blood Marrow Transplant 19(10):1416–1420. https://doi.org/10.1016/j.bbmt.2013.05.011CrossRef

34.

Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D (2015) Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis 74(11):2006–2015. https://doi.org/10.1136/annrheumdis-2013-205067CrossRefPubMed

35.

(2022) Benlysta (belimumab) [package insert]. GlaxoSmithKline, Philadelphia, PA

36.

Plüß M, Tampe B, Niebusch N, Zeisberg M, Müller GA, Korsten P (2020) Clinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus. Front Med 7(222). https://doi.org/10.3389/fmed.2020.00222

37.

Sjöwall C, Hjorth M, Eriksson P (2017) Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases. Lupus 26(12):1333–1338. https://doi.org/10.1177/0961203317691371CrossRefPubMed

38.

Alexander T, Cheng Q, Klotsche J, Khodadadi L, Waka A, Biesen R, Hoyer BF, Burmester GR, Radbruch A, Hiepe F (2018) Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors. Eur J Immunol 48(9):1573–1579. https://doi.org/10.1002/eji.201847492CrossRefPubMed

39.

(2022) Velcade (bortezomib) [package insert]. Takeda Pharmaceuticals America Inc, Lexington, MA

40.

Huehnchen P, Springer A, Kern J, Kopp U, Kohler S, Alexander T, Hiepe F, Meisel A, Boehmerle W, Endres M (2020) Bortezomib at therapeutic doses poorly passes the blood-brain barrier and does not impair cognition. Brain Commun 2(1):fcaa021. https://doi.org/10.1093/braincomms/fcaa021CrossRefPubMedPubMedCentral

41.

Karageorgas TP, Tseronis DD, Mavragani CP (2011) Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes. J Biomed Biotechnol 2011:273907. https://doi.org/10.1155/2011/273907CrossRefPubMedPubMedCentral

42.

Perry DK, Burns JM, Pollinger HS, Amiot BP, Gloor JM, Gores GJ, Stegall MD (2009) Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant : Off J Am Soc Transplant Am Soc Transplant Surg 9(1):201–209. https://doi.org/10.1111/j.1600-6143.2008.02461.xCrossRef

43.

Frohlich K, Holle JU, Aries PM, Gross WL, Moosig F (2011) Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma. Ann Rheum Dis 70(7):1344–1345. https://doi.org/10.1136/ard.2010.133256CrossRefPubMed

44.

Quartuccio L, Rupolo M, Michieli M, De Vita S (2014) Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus. Rheumatology (Oxford, England) 53(2):381–382. https://doi.org/10.1093/rheumatology/ket284CrossRefPubMed

45.

Taddeo A, Khodadadi L, Voigt C, Mumtaz IM, Cheng Q, Moser K, Alexander T, Manz RA, Radbruch A, Hiepe F, Hoyer BF (2015) Long-lived plasma cells are early and constantly generated in New Zealand Black/New Zealand White F1 mice and their therapeutic depletion requires a combined targeting of autoreactive plasma cells and their precursors. Arthritis Res Ther 17(1):39. https://doi.org/10.1186/s13075-015-0551-3CrossRefPubMedPubMedCentral

46.

Hofmann K, Clauder AK, Manz RA (2018) Targeting B cells and plasma cells in autoimmune diseases. Front Immunol 9:835. https://doi.org/10.3389/fimmu.2018.00835CrossRefPubMedPubMedCentral

47.

Groettrup M, Kirk CJ, Basler M (2010) Proteasomes in immune cells: more than peptide producers? Nat Rev Immunol 10(1):73–78. https://doi.org/10.1038/nri2687CrossRefPubMed

48.

Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, Enghard P, Richter U, Biesen R, Schneider U, Knebel F, Burmester G, Radbruch A, Mei HE, Mashreghi MF, Hiepe F, Alexander T (2020) Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med 383(12):1149–1155. https://doi.org/10.1056/NEJMoa2023325CrossRefPubMed

49.

Mei HE, Schmidt S, Dörner T (2012) Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res Ther 14(Suppl 5):S1. https://doi.org/10.1186/ar3909CrossRefPubMedPubMedCentral

50.

Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, Bae SC, Brohawn PZ, Pineda L, Berglind A, Tummala R (2020) Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 382(3):211–221. https://doi.org/10.1056/NEJMoa1912196CrossRefPubMed

Titel: Bortezomib is efficacious in the treatment of severe childhood-onset neuropsychiatric systemic lupus erythematosus with psychosis: a case series and mini-review of B-cell immunomodulation in antibody-mediated diseases
verfasst von: Renee F. Modica
Akaluck Thatayatikom
Denise H. Bell-Brunson
Melissa E. Elder
Publikationsdatum: 27.03.2023
Verlag: Springer International Publishing
Erschienen in: Clinical Rheumatology / Ausgabe 7/2023
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-023-06559-y

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2023

Microvascular damage evaluation based on nailfold videocapillarosopy in sarcoidosis

Negative ANA-IIF in SLE patients: what is beyond?

Incidence and prevalence of systemic sclerosis in Thailand in year 2017–2020: a database from the Ministry of Public Health

Cannabis arteritis presenting with Raynaud’s and digital ulcerations: a case-based review of a controversial thromboangiitis obliterans-like condition

The association between rheumatoid arthritis and reduced estimated cardiorespiratory fitness is mediated by physical symptoms and negative emotions: a cross-sectional study